# Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

> **NCT00467610** · PHASE2 · TERMINATED · sponsor: **Rush University Medical Center** · enrollment: 6 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Panhematin

## Key facts

- **NCT ID:** NCT00467610
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** lack of efficacy.
- **Last updated:** 2014-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467610, "Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00467610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*